earnings
confidence high
sentiment positive
materiality 0.65
Jasper Therapeutics reports Q3 2023 net loss of $17.5M; highlights IND clearance for briquilimab in CSU
Jasper Therapeutics, Inc.
2023-Q3 EPS reported
-$0.47
- Net loss of $17.5M ($0.16 per share); R&D expenses $14.8M; G&A expenses $4.5M.
- Cash and cash equivalents of $103.9M as of Sept 30, 2023.
- FDA cleared IND for Phase 1b/2a study of subcutaneous briquilimab in CSU; first patient expected by end of 2023.
- Stanford-sponsored Phase 1/2 study in Fanconi Anemia: all 3 patients achieved full donor engraftment.
- Appointed Thomas Wiggans as Chairperson and Herb Cross as CFO.